The immune cell landscape in kidneys of patients with lupus nephritisBetty Diamond, Arnon Arazi, Deepak A. Rao et al.|Nature Immunology|2019Cited by 840
A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritisGary S. Hoffman, María C. Cid, David B. Hellmann et al.|Arthritis & Rheumatism|2002Cited by 574
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard Furie, Raj Tummala, Eric F. Morand et al.|The Lancet Rheumatology|2019Cited by 478
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)Michelle Petri, Marta Mosca, Christina Dickson et al.|The Lancet|2023Cited by 164
A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth Kalunian, Hussein Al‐Mossawi, Richard Furie et al.|Arthritis & Rheumatology|2022Cited by 151